Fig. 2
From: Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2
SPECT quantification and biodistribution of 177Lu-m11B6. a SPECT quantification of 7.9 ± 0.69 MBq, 30 μg 177Lu-m11B6 in s.c. LNCaP-xenografted NMRI nude mice at 24, 48, 72, and 168 h. b. Biodistribution of 7.9 ± 0.69 MBq, 30 μg 177Lu-m11B6 in s.c. LNCaP at 72 and 168 h p.i. c In vivo specificity, 7.9 ± 0.69 MBq q, 30 μg 177Lu-m11B6 in s.c. LNCaP- and DU 145-xenografted NMRI nude mice at 72 h with a group of pre-dosed mice (1 mg cold m11B6 24 h pre-injection of labeled antibody)